MK2870-019_A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (TroFuse-019)

Objective

Clinical Trial Details

IRB Protocol Number

2025.025

Principal Investigator(s)

Amy N. Sanford, MD

Clinical Trial Categories

• Cancer
• Lung Cancer

Contact

Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org